Table 1.
Comparison of study subjects’ characteristics between VTE subsample and the remaining Genotyping and Molecular Phenotyping in Venous Thromboembolism project (GMP-VTE) sample.
| GMP-VTE | VTE Subsample | p-Value | |
|---|---|---|---|
| Number (N) | 513 | 180 | - |
| Sex (females), % (N) | 44.8 (230) | 40.0 (72) | 0.29 |
| Age (years), mean (SD) | 60.3 (15.9) | 60.9 (16.0) | 0.63 |
| BMI (kg/m²), median (IQR) | 28.3 (24.7/32.0) | 28.3 (24.5/31.9) | 0.85 |
| Platelet count (109/L), median (IQR) | 239.0 (189.7/297.3) | 221.5 (178.0/268.6) | 0.01 |
| Leukocytes (103/L), median (IQR) | 8.50 (6.53/11.30) | 8.48 (6.82/11.10) | 0.83 |
| Cardiovascular risk factors | |||
| Arterial hypertension, % (N) | 49.5 (249) | 55.8 (91) | 0.18 |
| Diabetes mellitus, % (N) | 12.4 (62) | 15.9 (26) | 0.29 |
| Smoking, % (N) | 16.9 (82) | 17.9 (29) | 0.81 |
| Obesity, % (N) | 35.5 (172) | 36.5 (65) | 0.85 |
| Comorbidities | |||
| Atrial fibrillation, % (N) | 4.2 (21) | 5.5 (9) | 0.52 |
| CHF, % (N) | 4.5 (22) | 6.1 (10) | 0.40 |
| CAD, % (N) | 7.1 (35) | 8.5 (14) | 0.61 |
| Stroke, % (N) | 5.0 (25) | 5.5 (9) | 0.84 |
| PAD, % (N) | 3.8 (12) | 6.1 (8) | 0.32 |
| Cancer, % (N) | 12.5 (63) | 11.8% (21) | 0.89 |
| VTE phenotype | |||
| Isolated PE, % (N) | 18.3 (86) | 21.1 (37) | 0.43 |
| Isolated DVT, % (N) | 30.4 (156) | 21.1 (38) | 0.02 |
| PE+DVT, % (N) | 48.6 (229) | 57.1 (100) | 0.06 |
| Therapy | |||
| Heparin, % (N) | 57.0 (292) | 67.8 (122) | 0.01 |
| FXa inhibitor, % (N) | 26.0 (133) | 23.3 (10) | 0.06 |
| Anticoagulants *, % (N) | 75.6 (387) | 80.6 (145) | 0.18 |
| Antiplatelets ** | 23.2 (119) | 33.9 (61) | 0.01 |
| Contraceptives, % (N) | 4.1 (21) | 6.7 (12) | 0.22 |
N, number; %, Percentages, based on non-missing information; SD, standard deviation; IQR, interquartile range; BMI, body mass index; CHF, chronic heart failure; CID, chronic inflammatory disease; CKD, chronic kidney disease; CLD, chronic liver disease; CAD, coronary artery disease; PAH, pulmonary arterial hypertension; PAD, peripheral artery disease; VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; includes agents with the following Anatomical Therapeutic Chemical codes: * B01AA, B01AB, and B01AF. ** Clopidogrel and acetylsalicylic acid.